The earnings headline was a clear miss. Candel reported a GAAP loss of $0.52 per share, versus a published consensus of approximately $0.23 loss per share, making the quarter materially worse than expected. The miss was driven largely by a $12.3 million unfavorable change in warrant-liability fair value, so it was primarily non-cash rather than a direct deterioration in clinical execution (Consolidated Statements of Operations).
| Metric | Q2 2026 | Q2 2025 / comparison | Read-through |
|---|---|---|---|
| Research and development expense | $19.8M | $7.0M | Higher trial and manufacturing spending (Consolidated Statements of Operations) |
| General and administrative expense | $6.9M | $4.2M | Higher commercial-readiness costs (Consolidated Statements of Operations) |
| Net loss | $(38.9)M | $(4.8)M | Warrant revaluation amplified the loss (Consolidated Statements of Operations) |
| Basic EPS | $(0.52) | $(0.09) | Below approximately $(0.23) consensus (Consolidated Statements of Operations) |
| Cash and equivalents | $201.6M | $119.7M at Dec. 31, 2025 | Runway projected into Q1 2028 (Balance Sheet Data; Cash Position) |
The clinical and regulatory story was mostly confirmation, not a fresh surprise. The 39% improvement in prostate cancer-specific disease-free survival came from data initially announced in December 2024 and extended follow-up presented in May 2026; publication in The Lancet Oncology adds validation but does not materially change the underlying evidence (Aglatimagene—Prostate Cancer). The first AURORA site activation, the commercial-chief appointment, and the Q4 2026 BLA target were also already disclosed or previously anticipated (Recent Corporate Events; Anticipated Milestones).
The operating picture is advancing, but at a higher cash-burn rate. R&D expense nearly tripled year over year as Candel funds manufacturing validation, the prostate BLA effort, and the new NSCLC phase 3 trial, while G&A rose with commercial preparation (Consolidated Statements of Operations). The company still says $201.6 million of cash funds its current plan into Q1 2028, including potential 2027 launch preparation, but that runway depends on the stated operating plan and does not remove regulatory or execution risk (Cash Position; Forward-Looking Statements).
Net read: a financial miss against a largely unchanged development narrative. The quarter did not weaken the prostate program's disclosed clinical results or delay the planned BLA, but it offered little new upside because the major milestones were already known. Against expectations, the warrant-driven EPS shortfall outweighs the steady pipeline update, producing a slight negative read.
Read the original 8-K on SEC EDGAR ↗